OncoMatch/Clinical Trials/NCT07140900
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Is NCT07140900 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including Xaluritamig and Darolutamide for metastatic hormone-sensitive prostate cancer (mhspc).
Treatment: Xaluritamig · Darolutamide · Abiraterone — The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Demographics
Prior therapy
Must have received: androgen deprivation therapy (lhrh agonist, lhrh antagonist, orchiectomy) — de novo mhspc
Cannot have received: docetaxel (docetaxel)
Cannot have received: steap1-targeted therapy
Cannot have received: radioligand therapy
Cannot have received: parp inhibitor
Cannot have received: cytotoxic chemotherapy
Cannot have received: aminoglutethimide (aminoglutethimide)
Cannot have received: ketoconazole (ketoconazole)
Cannot have received: systemic biologic therapy for prostate cancer
Cannot have received: radiotherapy to all metastatic sites of disease
Exception: radiotherapy to some sites of metastatic disease for palliation will be permitted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California San Francisco · San Francisco, California
- Dana Farber Cancer Institute · Boston, Massachusetts
- University of Minnesota · Minneapolis, Minnesota
- Cleveland Clinic Foundation · Cleveland, Ohio
- Thomas Jefferson University · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07140900 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior docetaxel, steap1-targeted therapy, radioligand therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages